The association of FAM155B expression with resistance to conventional chemotherapeutic agents like Tegafur and 5-fluorouracil derivatives suggests it may contribute to treatment failure in breast cancer patients (Botticelli et al., 2020). Here, NALF2 is linked to breast cancer.